| Identification | Back Directory | [Name]
H-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-OH | [CAS]
143413-47-2 | [Synonyms]
(ARG)9
RRRRRRRRR
Peptide R9
R 9 peptide
Nonaarginine
(Arg)9 peptide
H-RRRRRRRRR-NH2
Poly Arginine 9
Nona-L-arginine
H(-Arg)9-OH, Nonaarginine
Poly Arginine 9|(Arg)9 NJ-Peptide
Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg
Poly Arginine 9|(Arg)9 peptide|RRRRRRRRR
H-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-ARG-OH
L-Arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginine
L-Arginine,L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- | [Molecular Formula]
C54H110N36O10 | [MDL Number]
MFCD08458590 | [MOL File]
143413-47-2.mol | [Molecular Weight]
1423.69 |
| Chemical Properties | Back Directory | [density ]
1.60±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [Sequence]
H-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-OH |
| Hazard Information | Back Directory | [Biological Activity]
(Arg)9 (Nona-L-arginine; Peptide R9) is a cell-permeable polypeptide with IC50 value of 0.78 μM for neuroprotection in a glutamate model experimental model. | [in vitro]
Poly-arginine (eg (Arg)9) and arginine-rich peptides (eg TAT, penetratin), which belong to a class of peptides with cell-penetrating properties are neuroprotective. It provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC 50 =0.78 μM). Following kainic acid exposure, (Arg)9 is neuroprotective, but less effective than in the glutamic acid model (IC 50 =0.81 μM). (Arg)9 also shows neuroprotection following in vitro ischemia (IC 50 =6 μM). | [in vivo]
(Arg)9) (D-isoform) is neuroprotective in rat stroke models. (Arg)9) is highly neuroprotective, with efficacy increasing with increasing arginine content, has the capacity to reduce glutamic acid-induced neuronal calcium influx and requires heparan sulfate preotoglycan-mediated endocytosis to induce a neuroprotective effect. (Arg)9) (D-isoform) administered intravenously at a dose of 1000 nmol/kg 30 min after reduces permanent middle cerebral artery occlusion (MCAO) infarct volume . | [target]
IC50: 0.78 μM (neuroprotection) |
|
|